Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study

Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study

To deal with the COVID-19 pandemic, a mass vaccination campaign was started in European countries on 27 December 2020. The first vaccine available to immunize healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine. While many studies have shown a high antibody response after the second vac...

Full description

Bibliographic Details
Main Authors: Francesco Paolo Bianchi, Pasquale Stefanizzi, Cinzia Annatea Germinario, Giovanni Migliore, Luigi Vimercati, Andrea Martinelli, Annamaria Lobifaro, Giusy Diella, Angela Maria Vittoria Larocca, Control Room Working Group, Silvio Tafuri
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Vaccines
Subjects:
COVID-19
vaccine effectiveness
antibodies
documented infection
healthcare workers
Online Access:https://www.mdpi.com/2076-393X/10/3/417

Internet

https://www.mdpi.com/2076-393X/10/3/417

Similar Items